CONMED CORP (CNMD)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CNMD
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CNMD | President and CEO and Director | 58 | ["President and CEO and Director at Bio-Techne since 2024.","Previously served as Chief Operating Officer and President of Diagnostics and Genomics.","Formerly served in various senior leadership roles at Thermo Fisher Scientific and Becton, Dickinson and Co.","extensive global leadership experience across large and mid-cap life sciences businesses","strong track record in global operations, innovation and strategy","executive management experience","expertise leading the growth of biotechnology companies"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| TECH | President and CEO, Bio-Techne Corporation | 58 | ["Critical insight on Bio-Techne\u2019s commercial business", "Day-to-day operations management", "Extensive executive management experience", "Expertise leading the growth of biotechnology companies"] | [] | 2025 |
Biography sourced from the proxy statement filing.
President and Chief Executive Officer Bio-Techne Age: 58 Director Since: 2025 Independence: Yes Current Committees: Corporate Governance and Nominating (Since 2025), Strategy (Since 2025) Professional Experience: Bio-Techne Corporation (Nasdaq: TECH) President and Chief Executive Officer, Since 2024 Chief Operating Officer, 2023 - 2024 President, Diagnostics and Genomics Segment, 2018 - 2024 Thermo Fisher Scientific Inc. (NYSE: TMO) Led businesses of increasing size and complexity, including the Platforms and the Content of the Genetic Sciences Division, 2010 - 2018 Becton, Dickinson & Company (NYSE: BDX) Senior Segment Leader, 2006 - 2010 Other Public Company Boards: Bio-Techne Corporation (Nasdaq: TECH), Since 2024 Other Boards: Analytical, Life Science & Diagnostics Association, Since 2023 StatLab Medical Products, Since 2021 Education: Hogeschool Heerlen of Applied Sciences (Netherlands), Bachelor of Science Skills: Mr. Kelderman s qualifications for election to the Board include extensive global leadership experience across large and mid-cap life sciences businesses, with a strong track record in global operations, innovation and strategy. The Board and Company benefit from the perspective that Mr. Kelderman brings from extensive executive management experience and expertise leading the growth of biotechnology companies.